Health
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 – StreetInsider.com
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer anti-tumor activity, including in tumors exposed to prior lines…
April 10, 2021 8:30 AM EDT
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere.
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition
Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742
Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter…
-
Business20 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News19 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General14 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News16 hours agoTips to improve engagement – Proctor